Ocular Manifestations of Systemic Disease

Metabolic / microvascular

• Diabetes mellitus: chronic hyperglycemia with pericyte dropout and VEGF-driven neovascularization; the single strongest predictors are duration of disease and cumulative glycemic exposure.
• Dyslipidemia and hypercalcemia: lipid extravasation produces hard exudates and corneal arcus; calcium phosphate deposition in the interpalpebral cornea produces band keratopathy.
• Wilson disease: ATP7B mutation with corneal Descemet-membrane copper (Kayser-Fleischer ring) and sunflower cataract.

Hemodynamic

• Chronic and accelerated hypertension: autoregulatory arteriolar narrowing, then fibrinoid necrosis and blood-retinal barrier breakdown in malignant hypertension.

Immune-mediated

• HLA-B27 spondyloarthropathies, sarcoidosis, IBD, Behçet, JIA: non-infectious uveitis; sarcoidosis disproportionately affects Black patients in the US.
• Giant cell arteritis: granulomatous arteritis of the posterior ciliary arteries in patients over 50.
• Multiple sclerosis: demyelinating optic neuritis, typically a young woman.

Modifiable risk factors

• Hyperglycemia, blood pressure, dyslipidemia, smoking, obesity and obstructive sleep apnea, anemia, and nephropathy — the ADA Standards of Care emphasize glycemic and blood pressure control as the principal levers on retinopathy progression.
• Nonadherence to screening intervals; the ADA recommends dilated examination at diagnosis in type 2 diabetes and within 5 years of diagnosis in type 1, then at least biennially to annually depending on findings.
• Pregnancy accelerates existing retinopathy and warrants examination before conception and each trimester (ADA).

Non-modifiable risk factors

• Duration of diabetes, type 1 disease, age over 50 for GCA and arterial occlusion, female sex for MS and GCA, HLA-B27 and HLA-B51 haplotypes, family history, and race/ethnicity (sarcoidosis, sickle cell disease).

• Microvascular damage from chronic hyperglycemia and hypertension: Prolonged exposure to elevated glucose and blood pressure causes endothelial dysfunction, pericyte loss, basement membrane thickening, and increased vascular permeability. In diabetes, advanced glycation end products (AGEs) cross-link structural proteins and activate RAGE receptors, promoting oxidative stress and inflammation. Hypertensive changes include arteriolar narrowing, arteriovenous nicking, and cotton-wool spots from nerve fiber layer infarction.

• Autoimmune-mediated inflammation: Systemic lupus erythematosus, rheumatoid arthritis, and vasculitides trigger immune complex deposition and T-cell infiltration in ocular tissues, causing anterior/posterior uveitis, episcleritis, and scleritis. Granulomatous inflammation occurs in sarcoidosis and tuberculosis through Th1-driven cellular immunity.

• Metabolic and storage disorders: Lysosomal enzymes, lipids, or proteins accumulate in cornea, lens, retina, or optic nerve (e.g., gaucher cells in Gaucher disease, copper deposition in Wilson disease causing Kayser-Fleischer rings). Hyperlipoproteinemia causes lipid deposition in cornea and retina; hypercalcemia produces band keratopathy.

• Vascular occlusion and thrombosis: Hypercoagulable states (antiphospholipid syndrome, malignancy) and vasculitis promote retinal artery/vein occlusion. Sickle cell disease causes vaso-occlusive crises affecting retinal and choroidal vessels.

• Neoplastic infiltration and paraneoplastic effects: Direct tumor infiltration of uveal tract, optic nerve, or retina occurs with lymphomas and metastatic disease. Paraneoplastic syndromes (cancer-associated retinopathy, melanoma-associated retinopathy) produce autoantibodies against retinal photoreceptors causing vision loss.

• Cranial nerve and CNS involvement: Systemic diseases affecting the brain (multiple sclerosis, neurosyphilis, Lyme disease) manifest as optic neuritis, internuclear ophthalmoplegia, or cranial nerve palsies affecting extraocular muscles.

• Retinopathy in diabetes mellitus: Nonproliferative diabetic retinopathy (NPDR) presents with microaneurysms, dot-blot hemorrhages, hard exudates, and cotton-wool spots typically without visual symptoms until macula is involved. Proliferative diabetic retinopathy (PDR) features neovascularization of disc or elsewhere with risk of vitreous hemorrhage, tractional retinal detachment, and sudden vision loss. Diabetic macular edema causes blurred vision and metamorphopsia.

• Hypertensive retinopathy (Keith-Wagener classification): Grade 1-2 shows arteriolar narrowing and arteriovenous nicking; Grade 3 adds flame hemorrhages, cotton-wool spots, hard exudates, and macular star pattern; Grade 4 (hypertensive retinopathy) includes optic disc swelling (papilledema) with malignant hypertension presenting as acute vision changes, headache, and blood pressure >180/120 mmHg.

• Anterior uveitis in systemic disease: Presents with photophobia, eye pain, red eye, and blurred vision. Classic associations include HLA-B27-associated diseases (ankylosing spondylitis, inflammatory bowel disease, reactive arthritis), sarcoidosis (granulomatous with posterior synechiae), and syphilis (often chronic and insidious).

• Posterior uveitis and vitritis: Floaters, photopsia, and vision loss occur with toxoplasmosis (scarred focal chorioretinitis in immunocompromised), cytomegalovirus (hemorrhagic necrosis in AIDS), tuberculosis, and sarcoidosis. Sarcoidosis produces "candle-wax" periphlebitis and snowbank inflammation.

• Optic neuritis and optic neuropathy: Painful vision loss with central scotoma and afferent pupillary defect occur in multiple sclerosis (demyelinating optic neuritis), neurosyphilis (syphilitic optic atrophy), giant cell arteritis (sudden painless vision loss in elderly >50), and paraneoplastic syndromes.

• Retinal vascular occlusions: Central retinal artery occlusion (CRAO) causes sudden painless vision loss with cherry-red macula; associated with giant cell arteritis in elderly, thrombophilia, vasculitis, and cardioemboli. Central retinal vein occlusion (CRVO) presents with vision loss and "blood and thunder" fundus; associated with malignancy, antiphospholipid syndrome, and polycythemia.

• Conjunctival and episcleral signs: Jaundice causes yellow discoloration (hepatic disease), cyanosis from cardiopulmonary disease appears blue-purple, Roth spots (retinal hemorrhages with white centers from septic emboli) in bacterial endocarditis, and Osler nodes visible on conjunctiva in endocarditis.

• Kayser-Fleischer rings and corneal changes: Greenish-brown copper deposition in Descemet's membrane in Wilson disease; band keratopathy (calcium deposition in cornea) in hypercalcemia, chronic kidney disease, and sarcoidosis.

• Eyelid and orbital manifestations: Ptosis and ophthalmoplegia in myasthenia gravis (fatigable weakness), proptosis and lid retraction in Graves' disease (thyroid eye disease), periorbital edema in nephrotic syndrome and hypothyroidism, xanthelasmas in hyperlipidemia.

• Iris abnormalities: Heterochromia (Horner syndrome, Waardenburg syndrome, Fuchs heterochromic iridocyclitis), iris neovascularization in proliferative diabetic retinopathy and central retinal vein occlusion increasing glaucoma risk.

• Comprehensive dilated eye examination (gold standard): Direct and indirect ophthalmoscopy evaluate optic disc, macula, vessels, and peripheral retina; slit-lamp biomicroscopy assesses anterior segment (iris, lens, vitreous) for inflammation, cataracts, and keratic precipitates. Photography and optical coherence tomography (OCT) document changes and monitor progression, particularly in diabetic retinopathy and macular edema.

• Fluorescein angiography (FA) and indocyanine green angiography: FA reveals microaneurysms, retinal capillary nonperfusion, neovascularization, and macular edema patterns (diffuse vs. focal leakage). ICG penetrates media opacity better and shows choroidal circulation abnormalities in sarcoidosis and choroiditis.

• Systemic workup based on ocular findings: Uveitis workup includes HLA-B27 testing, ACE level and chest X-ray for sarcoidosis, FTA-ABS or RPR for syphilis, tuberculin skin test, and toxoplasma serology in immunocompromised. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) assess systemic inflammation; temporal artery biopsy in giant cell arteritis (>50 years old with vision loss and constitutional symptoms). Imaging (MRI brain/orbit) for demyelinating disease when optic neuritis suspected.

• Blood pressure and glucose monitoring: Diagnosis of hypertensive retinopathy requires BP measurement; severity correlates with fundoscopic findings. HbA1c and fasting glucose document glycemic control in diabetes; proliferative disease risk increases significantly with HbA1c >8% and duration >10 years.

Immediate stabilization (sight- or life-threatening)

• Suspected giant cell arteritis: start high-dose systemic glucocorticoids (methylprednisolone IV for vision loss, otherwise high-dose oral prednisone) before temporal artery biopsy — the ACR/Vasculitis Foundation guideline states biopsy yield is preserved for a short window and delay risks the fellow eye. Tocilizumab (IL-6 receptor antagonist) is recommended as a glucocorticoid-sparing adjunct.
• Central retinal artery occlusion: manage as an acute cerebral ischemic event — urgent stroke-center evaluation with vessel imaging and cardiac workup, per the AHA/ASA scientific statement. Ocular massage and anterior chamber paracentesis have no proven benefit.
• Grade 4 hypertensive retinopathy with papilledema = hypertensive emergency: IV titratable agents (dihydropyridine calcium channel blocker, e.g. nicardipine, or labetalol), lowering mean arterial pressure by no more than about 25% in the first hour per the ACC/AHA hypertension guideline — abrupt overcorrection can infarct the optic nerve.

First-line disease-directed therapy

• Diabetic eye disease: intensive glycemic, blood pressure and lipid control (ADA Standards of Care). For center-involving diabetic macular edema, intravitreal anti-VEGF (aflibercept, ranibizumab, bevacizumab) is first-line.
• Non-infectious anterior uveitis: topical corticosteroid (prednisolone acetate) plus a cycloplegic (cyclopentolate) to prevent posterior synechiae and relieve ciliary spasm.
• Optic neuritis: IV methylprednisolone hastens visual recovery without changing final acuity (Optic Neuritis Treatment Trial); disease-modifying therapy is decided with MRI lesion burden.

Escalation and definitive management

• Panretinal photocoagulation for high-risk proliferative diabetic retinopathy; pars plana vitrectomy for nonclearing vitreous hemorrhage or tractional retinal detachment.
• Steroid-sparing immunosuppression for chronic uveitis: methotrexate or mycophenolate, escalating to a TNF inhibitor (adalimumab, FDA-approved for non-infectious uveitis).
• Wilson disease: chelation with trientine or penicillamine, or zinc for maintenance, per AASLD; Kayser-Fleischer rings regress with treatment.

Contraindicated

• Low-dose oral prednisone alone for optic neuritis — associated with increased recurrence in the ONTT.
• Topical steroids before excluding herpetic or fungal keratitis.

Complications of the underlying disease

• Neovascular glaucoma: VEGF from an ischemic retina diffuses forward, producing iris and angle neovascularization that obstructs aqueous outflow. Signals: rubeosis iridis, markedly elevated intraocular pressure, pain, corneal edema. Emergency — irreversible optic nerve damage within hours to days.
• Vitreous hemorrhage: fragile neovascular fronds bleed with vitreous traction; sudden painless floaters or a red haze with loss of the fundus red reflex.
• Tractional retinal detachment: fibrovascular membranes contract and pull the retina off the RPE; progressive field loss with a taut, immobile retina on ultrasound. Urgent surgical referral.
• Fellow-eye blindness in giant cell arteritis: untreated posterior ciliary arteritis involves the second eye within days. Emergency.
• Posterior synechiae and pupillary-block angle closure in chronic uveitis: an irregular, non-dilating pupil with iris bombé.
• Cystoid macular edema and band keratopathy in long-standing uveitis and hypercalcemia; optic atrophy after optic neuritis or chronic papilledema.
• Exposure keratopathy and compressive optic neuropathy in thyroid eye disease — dyschromatopsia and a relative afferent pupillary defect signal optic nerve compression and are sight-threatening.

Complications of treatment

• Endophthalmitis after intravitreal injection: pain, hypopyon and vision loss days after the procedure. Emergency — vitreous tap and intravitreal antibiotics.
• Panretinal photocoagulation: ablation of peripheral retina causes permanent peripheral field constriction and impaired dark adaptation; may transiently worsen macular edema.
• Corticosteroids (topical, periocular or systemic): posterior subcapsular cataract and steroid-response ocular hypertension progressing to glaucoma — pressure must be monitored.
• Hydroxychloroquine: bull's-eye maculopathy with paracentral scotoma; AAO recommends baseline and annual screening with OCT and visual fields after five years, and weight-based dosing.
• Ethambutol: dose- and duration-dependent optic neuropathy with red-green dyschromatopsia.
• Systemic anti-VEGF exposure: theoretical arterial thromboembolic risk, relevant after recent stroke or MI.

• Sudden painless monocular vision loss in a patient over 50 with jaw claudication, scalp tenderness and a high ESR/CRP — the single best next step is high-dose glucocorticoids immediately, then temporal artery biopsy. Waiting for the biopsy is the classic wrong answer.
• Cherry-red spot with a pale retina = central retinal artery occlusion (the fovea is perfused by the choroid, so it stands out). Distinguish from the cherry-red spot of Tay-Sachs/Niemann-Pick, where the retina is otherwise normal and the patient is an infant. CRAO is a stroke equivalent — work it up as one.
• Blood and thunder fundus (diffuse hemorrhages in all four quadrants, dilated tortuous veins) = central retinal vein occlusion; think hyperviscosity, antiphospholipid syndrome, or glaucoma — not embolism.
• Bilateral internuclear ophthalmoplegia in a young woman is multiple sclerosis until proven otherwise: adduction failure with abducting nystagmus in the contralateral eye, from a medial longitudinal fasciculus lesion. Order MRI brain with gadolinium.
• Candle-wax drippings (segmental periphlebitis) plus bilateral hilar adenopathy and a granulomatous uveitis = sarcoidosis; mutton-fat keratic precipitates are the anterior-segment buzzword. Lacrimal gland involvement with parotitis and facial palsy is Heerfordt syndrome.
• Kayser-Fleischer rings are copper in Descemet membrane and are essentially universal in Wilson disease with neurologic involvement, but may be absent in purely hepatic presentation — a normal slit-lamp exam does not exclude Wilson disease. Check ceruloplasmin and 24-hour urinary copper.
• Roth spots (white-centered retinal hemorrhages) point to infective endocarditis, but also occur in leukemia and severe anemia — do not treat them as pathognomonic.
• Papilledema is bilateral disc swelling with preserved acuity and an enlarged blind spot; papillitis is unilateral with an afferent pupillary defect and a central scotoma. Confusing the two is the most common distractor in optic disc questions.